Literature DB >> 6980014

Locations of oligosaccharide chains in human alpha 1-protease inhibitor and oligosaccharide structures at each site.

L C Hodges, S K Chan.   

Abstract

Previous studies in this laboratory had shown that the alpha 1-protease inhibitor (alpha 1-PI) molecule contained two types of oligosaccharides, biantennary and triantennary. Cleavage of human alpha 1-protease inhibitor with CNBr resulted in three carbohydrate-containing fragments, I-III. Composition data revealed that each of these CNBr fragments contained one oligosaccharide chain. The oligosaccharide structure at each glycosylation site on each purified CNBr fragment was determined by compositional analysis, behavior on Con A affinity chromatography, and methylation analysis. From the results of these studies, we propose that fragment I contains one carbohydrate chain that can be of either the biantennary or triantennary type. On the other hand, fragments II and III each contain one carbohydrate chain exclusively by the biantennary type of complex N-glycoside.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6980014     DOI: 10.1021/bi00540a036

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  4 in total

1.  The identification of epitopic sites in human alpha 1-proteinase inhibitor.

Authors:  X J Zhu; S S Kang; K Hargrove; D Shochat; M Jarrells; M Mojesky; S K Chan
Journal:  Biochem J       Date:  1987-08-15       Impact factor: 3.857

2.  Z-type alpha 1-antitrypsin is less competent than M1-type alpha 1-antitrypsin as an inhibitor of neutrophil elastase.

Authors:  F Ogushi; G A Fells; R C Hubbard; S D Straus; R G Crystal
Journal:  J Clin Invest       Date:  1987-11       Impact factor: 14.808

3.  Chemical modification of human alpha 1-proteinase inhibitor by tetranitromethane. Structure-function relationship.

Authors:  S Mierzwa; S K Chan
Journal:  Biochem J       Date:  1987-08-15       Impact factor: 3.857

4.  Fucosylated forms of alpha-1-antitrypsin that predict unresponsiveness to chemotherapy in ovarian cancer.

Authors:  S Thompson; D Guthrie; G A Turner
Journal:  Br J Cancer       Date:  1988-11       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.